- MGC Pharma, a company specialising in the production of medical cannabis, has seen an increase of 50 per cent in orders. During the first month of
operationspurchase orders totalled $300,000
- A trial of the companies CogniCann medicine is expected to be completed a year early due to high levels of interest. The trial will look at the effects the medicine has on participants over 65 years with
MGC Pharma, a bio-pharma company who specialise in the medical cannabis industry, have seen a 50 per cent increase in orders to medical cannabis wholesaler and company, Health House International and Cannvalate.
During the company’s first month of operations roughly $300,000 was raised through purchase orders.
The company said it is dedicated to “creating and supplying superb cannabinoid based pharmaceutical products” with a focus on making phytomedicines readily available for pharmacies and patients.
A clinical trial testing MGC Pharma’s CogniCann medicine is expected to be completed one year ahead of schedule, due to a much larger than expected expression of interest.
The trial in conjunction with Notre Dame University, WA, will look at the effects the phytocannabinoids based medicine has on participants over 65 years with alzheimers and dementia.
A number of pre and post treatment surveys and focus groups will be organised with family members and carers of the participants to gage their perception on how well the treatment has worked.
The trial will go over 18 weeks and is expected to be completed by the second quarter of 2020.